The GLP-1 class (semaglutide, tirzepatide, etc.) has some of the strongest clinical trial evidence of anything discussed on this forum, large randomized outcome trials with hard endpoints, which is refreshing compared to most peptide threads.
My question is mechanistic: the cardiovascular outcome data looks real, but how much of that benefit is downstream of weight and glycemic improvement versus a direct vascular/anti-inflammatory effect? I've seen both claims made confidently and I can't tell which is actually supported.
Interested in how people read the mediation analyses here.